LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

Gogishvili, Miranda; Melkadze, Tamar; Makharadze, Tamta; Giorgadze, D.; Dvorkin, Mikhail; Penkov, Konstantin; Лактионов, К. К.; Nemsadze, Gia; Nechaeva, M.; Rozhkova, I.; Kalinka, Ewa; Geßner, Christian; Moreno‐Jaime, Brizio; Passalacqua, Rodolfo; Li, S.; McGuire, Kristina; Quek, Ruben G.W.; Gullo, Giuseppe; Rietschel, Petra

doi:10.1016/j.annonc.2021.08.2130

Cited by 14 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The preliminary results in terms of DIC and DI, nivolumab combined with ipilimumab, with or without CT, subsequently have been considered the most effective novel dual immunological applicability to treat NSCLC [ 19 , 30 , 31 ]. Since the data of the non-squamous NSCLC subgroup were not provided in the MYSTIC, CHOICE-01, Empower-Lung 3, and POSEIDON studies, these four studies were not included in this NMA [ 32 , 33 , 34 , 35 ]. There was no significant difference in OS and PFS among the four ICI-based therapies (BIC, IC, DI, and DIC).…”

Section: Discussionmentioning

confidence: 99%

Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis

Chai

Bai

et al. 2022

JCM

View full text Add to dashboard Cite

Background: A network meta-analysis was conducted to summarize randomized control trials and updated results to evaluate the efficacy and safety profiles of existing first-line therapies for advanced non-squamous non-small cell lung cancer (NSCLC) patients without known driver gene mutations. Patients and Methods: Eligible studies were identified following a systematic search of the Cochrane Library, PubMed, Embase, Web of Science, Wanfang Data, and the China Knowledge Resource Integrated Database from January 2000 to December 2021. Results: Nineteen trials involving 8176 patients with driver-gene-negative advanced non-squamous NSCLC were included. For patients with driver-gene-negative advanced NSCLC, immunotherapy + chemotherapy (IC) significantly prolonged overall survival (OS) (hazard ratio (HR), 0.80; 95% confidence intervals (CI): 0.67–0.95) and progression-free survival (PFS) (HR, 0.68; 95% CI: 0.53–0.86) compared with bevacizumab + chemotherapy (BC), with a similar objective response rate and incidence of ≥3 treatment-related adverse events (TRAEs) (risk ratios (RR), 0.98; 95% CI: 0.79–1.21/RR, 0.89; 95% CI: 0.61–1.28; respectively) compared with BC. IC yielded a superior PFS rate (HR, 1.59; 95% CI: 1.05–2.38) compared to BC in the subgroup of patients < 65 years old. Conclusions: Currently, IC is a more efficient first-line therapy for driver-gene-negative advanced non-squamous NSCLC patients, with prolonged PFS and OS, as well as a comparatively lower risk of ≥3 TRAEs compared to BC.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis

Chai

Bai

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Cemiplimab in combination with chemotherapy improved survival compared to placebo-chemotherapy in EMPOWER-Lung 3 (median OS 21.9 versus 13 months, HR 0.71, 95% CI 0.53–0.93) [ 77 ]. Exploratory analysis by smoking status demonstrated that ever smokers derived much greater benefit (HR 0.61, 95% CI 0.46–0.82) than never smokers, who appeared not to benefit at all with addition of ICI (HR 1.28, 95% CI 0.53–3.08).…”

Section: Moving Into Clinic–anti-pd(l)1 Checkpoint Inhibitors Smoking...mentioning

confidence: 99%

Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer

Corke

Leighl

et al. 2022

Current Oncology

View full text Add to dashboard Cite

Tobacco is a known risk factor for lung cancer, and continued tobacco use is associated with poorer outcomes across multiple lung cancer treatment modalities including surgery, chemotherapy and radiation therapy. Less is known about the association of tobacco use and outcomes with immune checkpoint inhibitors (ICIs), which are becoming an important part of the treatment landscape in lung cancer, both in metastatic and curative settings. We reviewed the literature on the association of tobacco and tumor biology as it relates to immunotherapy. We also reviewed the association of tobacco use on outcomes among phase III randomized clinical trials involving ICIs in non-small cell lung cancer (NSCLC). We identified that patients with a smoking history may have a greater benefit with ICI treatment compared to never smokers in both treatment-naïve (HR 0.82, 95% CI 0.69–0.97, vs. HR 1.06, 95% CI 0.81–1.38) and pre-treated (HR 0.79, 95% CI 0.70–0.90 vs. 1.03, 95% CI 0.74–1.43) settings. In trials where smoking status was further defined, ex-smokers appear to demonstrate greater benefit with ICI therapy compared to current smokers (HR 0.78, 95% CI 0.59–1.01 vs. 0.91, 95% CI 0.72–1.14). We conclude by offering our perspective on future directions in this area of research, including implementation of standardized collection and analysis of tobacco use in clinical trials involving ICI therapy in lung cancer and other disease sites, and also evaluating how tobacco may affect toxicities related to ICI therapy. Based on our review, we believe that a patient’s history of tobacco smoking does have a role to play in guiding treatment decision making in patients with lung cancer.

show abstract

“…The median OS was seen to be improved by 8.9 months. Additionally, the combination group had a consistent safety profile and was linked to higher PFS, ORR, and longer duration of response [115]. Cemiplimab was proved to be efficacious with chemotherapy against a placebo.…”

Section: Icis In Combination With Chemotherapymentioning

confidence: 94%

Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer

Khadela

Chavda

Postwala

et al. 2023

Cancers

View full text Add to dashboard Cite

Immune checkpoints are unique components of the body’s defense mechanism that safeguard the body from immune responses that are potent enough to harm healthy body cells. When proteins present on the surface of T cells recognize and bind to the proteins present on other tumor cells, immune checkpoints are triggered. These proteins are called immunological checkpoints. The T cells receive an on/off signal when the checkpoints interact with companion proteins. This might avert the host’s immune system from eliminating cancer cells. The standard care plan for the treatment of non-small cell lung cancer (NSCLC) has been revolutionized with the use of drugs targeting immune checkpoints, in particular programmed cell death protein 1. These drugs are now extended for their potential to manage SCLC. However, it is acknowledged that these drugs have specific immune related adverse effects. Herein, we discuss the use of immune checkpoint inhibitors in patients with NSCLC and SCLC, their outcomes, and future perspectives.

show abstract

LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)

Cited by 14 publications

References 0 publications

Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis

Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis

Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer

Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer

Contact Info

Product

Resources

About